Holmes Biopharma, Inc.: Largest Single Contract to Date
January 09 2008 - 9:00AM
Marketwired
SCOTTSDALE, ARIZONA announces the signing of a $1.6 million
contract with a major biotech company for conducting a Phase 1
trial at the company's facility in Omaha, Nebraska. This is the
largest single contract signed to date, and brings the total of
committed contracts in 2007 to $13 million.
"This large contract and our first years sales results are
evidence that our aggressive growth strategy for 2008 is well under
way, and reaffirms the confidence our clients have in our clinical
research work," stated John Metcalfe, CEO of Holmes Biopharma
Inc.
About Holmes:
Holmes Biopharma Inc. and it's wholly owned subsidiary, Qualia
Clinical Service, Inc. is a contract research organization focused
on providing integrated and cost effective clinical development
services. Currently, clinics operate in Omaha, Nebraska, USA,
Toronto, Canada, and Kiev, Ukraine, Eastern Europe. For more
information about the company please visit our website at
www.holmesbiopharma.com.
On behalf of the Board of Directors
John F. Metcalfe, President, CEO
Certain statements in this press release constitute "forward
looking statements" within the meaning of the United States
Securities Legislation. The Company's actual results could differ
from those in the forward-looking statements. Do not construe this
information as investment advice. This is not a solicitation to buy
or sell securities. This does not purport to be a complete analysis
of the Company. Investing in securities is speculative and carries
a high degree of risk. Past performance does not guarantee future
results. Readers should consult their own independent advisers with
any investment, including any contemplated investment. All
information contained in this press release should be independently
investigated. This press release contains forward-looking
statements. These remarks involve risks and uncertainties. Risks
are not limited to quarterly fluctuations in results or the
companies' management of growth and competition. Other risks are
detailed in the Company's SEC filings. Actual results may differ
materially from such information set forth herein.
Contacts: Holmes Biopharma, Inc. John F. Metcalfe President, CEO
1-800-778-4990 Email: ir@holmesbiopharma.com Website:
www.holmesbiopharma.com
Swiftsure (CE) (USOTC:HLMB)
Historical Stock Chart
From Jul 2024 to Aug 2024
Swiftsure (CE) (USOTC:HLMB)
Historical Stock Chart
From Aug 2023 to Aug 2024